Evidence map›Paper›PMID 37875743›Full record

Trial reportJournal of cancer education : the official journal of the American Association for Cancer Education2024

A Novel Digital Educational Strategy Improves Treatment Adherence and Quality of Life in Patients with Multiple Myeloma.

Juan Guio, Andrés Melo, Mateo Mejía Saldarriaga, Cynthia Fuentes, Natalia Tíjaro-Ovalle, Andrés Borda, Yuli Guzmán, Elías Bolaños, Guillermo Quintero, Mónica Duarte and 10 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of cancer education : the official journal of the American Association for Cancer Education, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 3 countries.

Juan GuioCenter of Excellence for Multiple Myeloma, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.ORCID 0000-0003-0235-3195
Andrés MeloCenter of Excellence for Multiple Myeloma, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.ORCID 0000-0002-9840-8850
Mateo Mejía SaldarriagaHematology and Oncology Division, Weill Cornell Medicine/New York Presbyterian, New York, NY, USA.ORCID 0000-0002-3504-5597
Cynthia FuentesCenter of Excellence for Multiple Myeloma, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.ORCID 0000-0002-4560-4487
Natalia Tíjaro-OvalleInternal Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0003-1545-1253
Andrés BordaCenter of Excellence for Multiple Myeloma, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Yuli GuzmánCenter of Excellence for Multiple Myeloma, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Elías BolañosEducation and Knowledge Management, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Guillermo QuinteroCenter of Excellence for Multiple Myeloma, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.ORCID 0000-0002-3671-6911
Mónica DuarteCenter of Excellence for Multiple Myeloma, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.ORCID 0000-0002-6132-7272
Claudia AgudeloCenter of Excellence for Multiple Myeloma, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.ORCID 0000-0002-3174-3208
Soraya AparicioCenter of Excellence for Multiple Myeloma, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Gina CuellarCenter of Excellence for Multiple Myeloma, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Patricia BernalCenter of Excellence for Multiple Myeloma, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.ORCID 0000-0001-7885-5007
Marco PaézCenter of Excellence for Multiple Myeloma, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.ORCID 0000-0003-1737-8897
Erica RuedaCenter of Excellence for Multiple Myeloma, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Agustina RodriguezCenter of Excellence for Multiple Myeloma, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Fernando AlvaradoCenter of Excellence for Multiple Myeloma, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Oscar PinzónEnterprise Analytics Division, Memorial Hermann Health System, Houston, TX, USA.ORCID 0009-0007-5045-2864
Martha RomeroCenter of Excellence for Multiple Myeloma, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia. martha.romero@fsfb.org.co.ORCID 0000-0003-0376-9707
Fundación Santa Fe de Bogotá · COCornell University · USHospital Clínico San Carlos · ESMemorial Hermann · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma, the second most common hematologic malignancy worldwide, is an aggressive disease with high morbidity and mortality rates. Although myeloma remains incurable, new treatments have improved patients' life expectancy and quality of life. However, as these therapies are administered for prolonged and often indefinite periods, their success depends on high treatment adherence and significant patient engagement. This study aimed to evaluate the impact of a novel digital educational strategy on treatment adherence, quality of life, and the development of complications in patients with newly diagnosed myeloma. To this end, a two-arm, randomized, prospective, double-blind study was conducted to compare the conventional educational approach alone or combined with the novel digital strategy. This strategy was based on some principles of the Persuasive Systems Design model and incorporated the educational recommendations of patients and caregivers. Compared to the control group that only received information through the conventional educational approach, patients randomized to the digital strategy showed significantly higher treatment adherence and quality of life, associated with increased functionality and rapid reincorporation into daily routines. The digital strategy empowered patients and caregivers to understand the disease and therapeutic options and helped patients recall treatment information and implement healthy lifestyle habits. These results support that patient-targeted educational strategies can positively influence treatment adherence and thus improve their quality of life.

Indexed as

Multiple MyelomaHumansLife StyleProspective StudiesQuality of LifeTreatment Adherence and ComplianceDigital education programMedication adherenceMultiple myelomaQuality of life

Identifiers

PMID37875743
OpenAlexW4387902995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.